LABU's Recent Performance: -14.7% Drop Over 30 Days as Biotech Weakness Persists

Key Takeaways

• LABU declined approximately 14.7% over the trailing 30 days, reflecting amplified weakness in the underlying biotechnology index.
• The fund's 3x daily leverage magnifies both gains and losses, making it substantially more volatile than a standard biotech ETF.
• Quarterly performance is also negative, with the fund down roughly 13.5% over the past three months despite a strong rally in August.
• The portfolio is concentrated in small- and mid-cap, high-beta biotechnology companies, a segment highly sensitive to risk appetite and interest-rate expectations.
• Primary drivers include sector-wide biotech pullbacks, elevated volatility, and the compounding effects of daily reset leverage during choppy markets.
• For additional context, explore Price Targets and Forecast pages to review technical levels and projections.
• Discover automated strategies by exploring Trending AI Robots.

Understanding LABU's Structure and Holdings

LABU is a leveraged exchange-traded fund managed by Direxion that seeks daily investment results equal to 300% of the performance of the S&P Biotechnology Select Industry Index. It was launched in May 2015 and is classified as non-diversified. Because the leverage objective resets each day, the fund is designed for short-term trading rather than long-term buy-and-hold positioning.

The fund carries a net expense ratio of 0.96% and holds roughly $576 million in net assets. Its exposure is achieved primarily through total return swaps on the underlying index, supplemented by cash instruments and direct holdings in individual biotechnology companies. Sector allocation is effectively 100% healthcare, concentrated in biotechnology. Among the underlying equity names, positions are spread thinly across numerous small- and mid-cap issuers, including Moderna, Natera, Regeneron, Vertex, Gilead, Amgen, United Therapeutics, and Biogen, with most individual weightings below 1% of the portfolio.

This structure means LABU's performance is driven less by any single stock and more by the broad direction of the biotechnology sub-industry, amplified threefold on a daily basis. When the index falls, LABU tends to fall roughly three times as much in a single session, and persistent declines can compound into outsized losses over multi-week periods. I also checked comparable holdings using Tickeron’s AI Screener to see how the fund stacks up against peers.

Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, LABU fell approximately 14.7%, moving from an adjusted closing level near 257 to roughly 219. The decline was not linear; the fund traded through a choppy range before breaking lower in October, illustrating the amplified volatility typical of leveraged vehicles.

The quarterly picture is similar. Measured over the past three months, the fund is down roughly 13.5%. This hides significant intra-period swings, however: LABU rallied sharply in mid-August to a closing high near 341 before reversing into a sustained drawdown that carried it below 200 at its October low. The result is a trend that has been directionally negative over the trailing quarter but punctuated by rapid, high-magnitude moves in both directions. From what I see in the charts, the daily reset feature played a notable role in the magnitude of these swings.

Drivers Behind the Recent 30-Day Decline

The primary driver of the recent decline is the fund's 3x daily leverage applied to a weakening biotechnology index. The S&P Biotechnology Select Industry Index is heavily weighted toward smaller, earlier-stage, and clinical-phase biotech companies that carry elevated beta and are especially sensitive to shifts in investor risk appetite. When broad sentiment toward speculative growth assets deteriorates, these names often underperform, and LABU's leverage converts that underperformance into a much larger drawdown.

Structural factors reinforced the move. Biotechnology firms frequently rely on long-dated, uncertain cash flows and periodic capital raises, making the segment more responsive to changes in interest-rate expectations and financing conditions than more defensive healthcare subsectors. A rotation away from high-beta, unprofitable growth names pressured many of the fund's underlying holdings, while daily reset leverage compounded losses during a stretch of back-and-forth, range-bound trading.

Factors Behind the Quarterly Performance

The broader three-month trend reflects a period of elevated volatility in biotechnology rather than a single catalyst. LABU's August surge was consistent with a temporary rebound in risk appetite that lifted the underlying index, only to give way to renewed selling as market conditions turned more cautious. The subsequent drawdown outpaced the index's own decline because of the daily compounding of leveraged returns.

Longer-term themes also weighed on the segment. Biotechnology has faced a more selective funding environment and heightened sensitivity to monetary-policy signals, which tends to favor larger, profitable pharmaceutical names over the small- and mid-cap issuers that dominate this index. These dynamics, combined with the inherent drag of daily-reset leverage during choppy markets, help explain why the fund's three-month result is negative despite a notable mid-period rally. I reviewed similar patterns with Tickeron’s AI Pattern Search Engine for added perspective.

LABU ETF Outlook: What to Watch Next

Going forward, the most important factors for LABU are the trajectory of the biotechnology index itself and the persistence of market volatility. Because the fund resets its leverage daily, investors should monitor the direction and, critically, the consistency of moves in the underlying index, as choppy conditions can erode returns even when the index ends a period little changed. Interest-rate expectations, inflation data, and the broader appetite for risk assets are likely to remain key macro influences on small- and mid-cap biotech valuations.

Investors should also track the financing environment for early-stage biotechnology companies, clinical trial and regulatory developments across the sector, and any shifts in capital flows between leveraged and unleveraged biotech products. These themes, rather than any single company, are most likely to shape the fund's performance in the months ahead. I'm watching this closely as the sector navigates ongoing macro pressures.

Using Tickeron’s AI Screener for Sector Analysis

In my own research process, Tickeron’s AI Screener has proven useful for quickly scanning leveraged ETFs and biotech names against technical and volatility metrics. It allows me to filter for patterns and compare candidates efficiently without manual effort, helping refine views on funds like LABU in the context of broader sector moves.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Allana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume